Innovent Biologics Secures NRDL Inclusion for Seven Innovative Medicines in China
Innovent Biologics secures inclusion of seven innovative medicines in China's updated NRDL 2026, expanding reimbursement coverage across oncology, metabolic, cardiovascular and autoimmune diseases.
Tabosun | 16/11/2026 | By News Bureau
Innovent TABOSUN Becomes China's First Approved Domestic Anti CTLA 4 Antibody
Innovent Biologics has received approval from China’s National Medical Products Administration (NMPA) for TABOSUN (Ipilimumab N01 Injection), marking the country’s first domestically developed anti-CTLA-4 monoclonal antibody and a significant milestone in China’s immuno-oncology landscape.
TABOSUN | 26/12/2025 | By News Bureau | 595
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy